Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Find a Doctor

Michael J. Worley Jr., MD

Surgical Oncology

 No Ratings Available - Why Not? Make an Appointment

Physician

  • Director of Ovarian Cancer Surgery, Division of Gynecologic Oncology, Brigham and Women’s Hospital
  • Assistant Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Centers/Programs

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3669 (follow-up)
  • Office Phone Number617-732-8843
  • Fax617-632-3479
Make an Appointment

Bio

Dr. Worley Jr. received his medical degree from Florida State University College of Medicine in 2007. He subsequently completed his residency in Obstetrics and Gynecology at New York Presbyterian Hospital-Weill Cornell Medical College in 2011, and his fellowship in Gynecologic Oncology at Brigham and Women’s Hospital, Harvard Medical School in 2014. He is board-certified in Gynecologic Oncology and is a surgeon in the Division of Gynecologic Oncology. His clinical expertise includes: complex gynecologic surgery, surgery for advanced stage ovarian/fallopian tube/peritoneal cancer and robotic surgery.

Fellowship:

  • Brigham and Women's Hospital-Harvard Medical School, Gynecologic Oncology

Residency:

  • New York Presbyterian Hospital-Weill Cornell Medical College, Obstetrics and Gynecology

Medical School:

  • Florida State University College of Medicine

Research



For patients with advanced-stage ovarian/fallopian tube/peritoneal cancer, the quality of their initial surgery remains the most influential factor related to long-term survival. My research interests include improving the quality of surgical care delivered to these patients, so both short-term postoperative outcomes, as well as long-term survival, can be optimized.
I have published numerous articles regarding the appropriate use of primary cytoreductive surgery and neoadjuvant chemotherapy. These publications have provided clarity into what patient populations are ideally suited for each treatment approach. In addition, my research efforts have helped refine the overall goals of surgical resection, as well as management strategies to achieve the best surgical outcome.
I have lectured both locally and nationally on the topic of surgical resection of advanced-stage ovarian/fallopian tube/peritoneal cancer. In addition, I have been awarded the Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine (Harvard Medical School) in support of my research efforts.



Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
View in: PubMed

Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol. Gynecol Oncol. 2021 Aug; 162(2):353-359.
View in: PubMed

Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Gynecol Oncol. 2021 Jul; 162(1):56-64.
View in: PubMed

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
View in: PubMed

Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Gynecol Oncol. 2021 07; 162(1):12-17.
View in: PubMed

Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Mar 08.
View in: PubMed

Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 Jul; 86(1):e13394.
View in: PubMed

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
View in: PubMed

Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020 12; 159(3):687-691.
View in: PubMed

Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
View in: PubMed

Serous borderline tumor of the ovary with isolated cardiophrenic lymph node spread at diagnosis. Gynecol Oncol Rep. 2020 Aug; 33:100586.
View in: PubMed

Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020 06; 157(3):700-705.
View in: PubMed

Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol. 2019 09; 154(3):595-601.
View in: PubMed

A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
View in: PubMed

Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol. 2019 05; 114:32-36.
View in: PubMed

Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
View in: PubMed

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2019 02 05; 116(6):2210-2219.
View in: PubMed

Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
View in: PubMed

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
View in: PubMed

Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
View in: PubMed

Trends in Place of Death Among Patients With Gynecologic Cancer in the United States. Obstet Gynecol. 2018 06; 131(6):1111-1120.
View in: PubMed

The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
View in: PubMed

Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
View in: PubMed

Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol. 2017 08; 146(2):334-339.
View in: PubMed

Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
View in: PubMed

Molecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer. 2015 Sep; 51(13):1831-42.
View in: PubMed

Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
View in: PubMed

Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Aug 15; 137(4):776-83.
View in: PubMed

Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol Cancer. 2014 Oct; 24(8):1434-40.
View in: PubMed

Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
View in: PubMed

Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2014 Jun; 24(5):941-5.
View in: PubMed

An update on Mullerian-inhibiting substance: its potential application against ovarian cancer. Endocr Relat Cancer. 2014 Jun; 21(3):R227-33.
View in: PubMed

What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
View in: PubMed

Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013 Mar 06; 14(3):5367-79.
View in: PubMed

Preoperative leukocytosis imposes an increased risk of recurrence and death among patients with nonendometrioid endometrial carcinoma. Int J Gynecol Cancer. 2013 Feb; 23(2):312-7.
View in: PubMed

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
View in: PubMed

Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology. Int J Gynecol Cancer. 2013 Jan; 23(1):208-15.
View in: PubMed

Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. . 2012 Aug 01; 11(15):2876-84.
View in: PubMed

Lynch Syndrome: Awareness among Medical Students at a United States Medical School. Curr Womens Health Rev. 2012 Aug; 8(3):242-247.
View in: PubMed

The significance of preoperative leukocytosis in endometrial carcinoma. Gynecol Oncol. 2012 Jun; 125(3):561-5.
View in: PubMed

Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol. 2012 Apr; 125(1):241-4.
View in: PubMed

Adolescent Understanding and Acceptance of the HPV Vaccination in an Underserved Population in New York City. J Oncol. 2012; 2012:904034.
View in: PubMed

Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies. Gynecol Oncol. 2012 Apr; 125(1):48-53.
View in: PubMed

Robotic radical parametrectomy for unstaged invasive endometrial carcinoma. Int J Gynaecol Obstet. 2011 Nov; 115(2):208-9.
View in: PubMed

Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine. Vaccine. 2011 Jun 20; 29(28):4618-22.
View in: PubMed

Physician knowledge of and adherence to the revised breast cancer screening guidelines by the United States Preventive Services Task Force. Am J Obstet Gynecol. 2011 Sep; 205(3):201.e1-5.
View in: PubMed

Minimally invasive staging of endometrial cancer is feasible and safe in elderly women. J Minim Invasive Gynecol. 2011 Mar-Apr; 18(2):200-4.
View in: PubMed

Emerging therapeutics for primary peritoneal cancer. Expert Opin Emerg Drugs. 2011 Mar; 16(1):71-84.
View in: PubMed

Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. Appl Immunohistochem Mol Morphol. 2010 Dec; 18(6):509-11.
View in: PubMed

The significance of a thickened endometrial echo in asymptomatic postmenopausal patients. Maturitas. 2011 Feb; 68(2):179-81.
View in: PubMed

A case report of hereditary leiomyomatosis and renal cell cancer. Am J Obstet Gynecol. 2010 Jun; 202(6):e8-9.
View in: PubMed

Enterobius vermicularis infestation of a hysterectomy specimen in a patient with a colonic reservoir. Am J Obstet Gynecol. 2009 Jun; 200(6):e6-7.
View in: PubMed

Complications of laparoscopy in benign and oncologic gynecological surgery. Rev Obstet Gynecol. 2009; 2(3):169-75.
View in: PubMed

A statewide breast cancer screening project. Cancer Nurs. 1993 Oct; 16(5):347-53.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Top